Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug interaction study aims to make atumelnant safer

NCT ID NCT07570082

Ongoing Knowledge-focused Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study is testing how a new drug called atumelnant interacts with other medications in 46 healthy adults. Participants will receive atumelnant along with drugs like carbamazepine, midazolam, digoxin, and metformin to see how the body processes them. The goal is to gather safety and dosing information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atumelnant (also known as CRN04894), carbamazepine, midazolam, digoxin, metformin
What this could lead to
If successful, this study will help doctors understand how to safely dose atumelnant with other medications, reducing the risk of harmful drug interactions.
What could go wrong
This is an early-phase trial in healthy volunteers, not patients. The results may not predict effects in people with diseases, and drug interactions could still occur in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

  • Crinetics Study Site

    Lincoln, Nebraska, 68502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.